Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (785)	12/29/1999 10:20:00 AM
From: aknahow	Respond to of 3158

Sort of like the cat crossing the road. KUWTJ is keeping up with the Joneses. Sad to say but I really think that is the case. Why did so many big pharmas buy up ag related companies only to decide many years later as a group that that they were not good fits? Thanks for biting. Was about to take my pole out of the water and put it someplace else.

To: Biomaven who wrote (785)	12/29/1999 3:11:00 PM
From: biowa	Read Replies (1) \| Respond to of 3158

Peter, Add this to the Cat Algorithm: wait until the desire to cross or the fear of not crossing exceeds the fear of crossing That is - if this rally survives the H&Q effect and the mid-January correction some talking heads are predicting - then big pharma/bio may be motivated to move before the targets get any MORE expensive. Add to that KUWTJ. But this is probably the most positive munch scenario. biowa

To: Biomaven who wrote (785)	12/31/1999 12:10:00 PM
From: Jim H	Read Replies (2) \| Respond to of 3158

Peter, thanks for all your excellent contributions to the SI biotech boards. Wish I could contribute more, but I lack the expertise. Don't believe that I have seen anyone mention ERGO Science Corp (ERGO) on this board. Sells for about half of its cash on hand. No lawsuits that I can see. Currently working with FDA regarding safety issues on its diabetes drug. Slow burn rate. biz.yahoo.com An acquirer could pay double the current market price for the shares, get enough cash in the company to fund the entire purchase, and get drug candidate and research base for nothing. Of course a friendly takeover would be required since insiders own most of the shares. Any comments? JimH